Olema CFO/COO Kovacs departs Jan 30; CEO Bohen interim principal financial officer

Olema Pharmaceuticals, Inc.

Shane Kovacs, COO and CFO, leaves Jan 30, 2026; not due to disagreement with company on financial operations.
Kovacs receives $621,283 lump sum: $562,640 salary, $23,443 prorated 2026 bonus, $35,200 COBRA.
Outstanding equity awards continue vesting while he consults through Aug 1, 2026.
CEO Sean Bohen, M.D., Ph.D., assumes interim principal financial officer role; search for permanent CFO launched.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.